These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Rodriguez R; Moreno A; Guzman F; Calvo M; Patarroyo ME Am J Trop Med Hyg; 1990 Oct; 43(4):339-54. PubMed ID: 2240362 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. Amador R; Moreno A; Murillo LA; Sierra O; Saavedra D; Rojas M; Mora AL; Rocha CL; Alvarado F; Falla JC J Infect Dis; 1992 Jul; 166(1):139-44. PubMed ID: 1607685 [TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698 [TBL] [Abstract][Full Text] [Related]
8. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas. Ferreira-da-Cruz MF; Deslandes DC; Oliveira-Ferreira J; Montenegro-James S; Tartar A; Druilhe P; Daniel-Ribeiro CT Parasite; 1995 Mar; 2(1):23-9. PubMed ID: 9137641 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW Malar J; 2016 Mar; 15():159. PubMed ID: 26975721 [TBL] [Abstract][Full Text] [Related]
10. Muramyl peptide adjuvants for Plasmodium falciparum and Plasmodium vivax circumsporozoite vaccines in rodent model systems. Bathurst IC; Gibson HL; Kansopon J; Hahm BK; Hollingdale MR; Barr PJ Biotechnol Ther; 1992; 3(1-2):15-34. PubMed ID: 1305890 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC). Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348 [TBL] [Abstract][Full Text] [Related]
12. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. Noya O; Gabaldón Berti Y; Alarcón de Noya B; Borges R; Zerpa N; Urbáez JD; Madonna A; Garrido E; Jimenéz MA; Borges RE J Infect Dis; 1994 Aug; 170(2):396-402. PubMed ID: 8035026 [TBL] [Abstract][Full Text] [Related]
13. Serological responses of Gambian children to immunization with the malaria vaccine SPf66. Metzger WG; Haywood M; D'Alessandro U; Drakeley CJ; Weiss H; Bojang K; Targett GA; Greenwood BM Parasite Immunol; 1999 Jul; 21(7):335-40. PubMed ID: 10417667 [TBL] [Abstract][Full Text] [Related]
14. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin. Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208 [TBL] [Abstract][Full Text] [Related]
15. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity. Amador R; Moreno A; Valero V; Murillo L; Mora AL; Rojas M; Rocha C; Salcedo M; Guzman F; Espejo F Vaccine; 1992; 10(3):179-84. PubMed ID: 1557934 [TBL] [Abstract][Full Text] [Related]
16. Protection of Aotus monkeys after immunization with recombinant antigens of Plasmodium falciparum. Enders B; Hundt E; Knapp B Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():413-22. PubMed ID: 1343721 [TBL] [Abstract][Full Text] [Related]
17. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Patarroyo G; Franco L; Amador R; Murillo LA; Rocha CL; Rojas M; Patarroyo ME Vaccine; 1992; 10(3):175-8. PubMed ID: 1557933 [TBL] [Abstract][Full Text] [Related]
18. A Plasmodium falciparum malaria vaccine candidate which contains epitopes from the circumsporozoite protein and a blood stage antigen, 5.1. Caspers P; Etlinger H; Matile H; Pink JR; Stüber D; Takács B Mol Biochem Parasitol; 1991 Aug; 47(2):143-50. PubMed ID: 1719416 [TBL] [Abstract][Full Text] [Related]
19. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Egan AF; Blackman MJ; Kaslow DC Infect Immun; 2000 Mar; 68(3):1418-27. PubMed ID: 10678955 [TBL] [Abstract][Full Text] [Related]